KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Assets Average (2016 - 2025)

Acadia Pharmaceuticals has reported Assets Average over the past 15 years, most recently at $1.4 billion for Q4 2025.

  • Quarterly results put Assets Average at $1.4 billion for Q4 2025, up 33.74% from a year ago — trailing twelve months through Dec 2025 was $1.4 billion (up 33.74% YoY), and the annual figure for FY2025 was $1.4 billion, up 42.09%.
  • Assets Average for Q4 2025 was $1.4 billion at Acadia Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • Over the last five years, Assets Average for ACAD hit a ceiling of $1.4 billion in Q4 2025 and a floor of $595.2 million in Q4 2022.
  • Median Assets Average over the past 5 years was $730.4 million (2021), compared with a mean of $840.0 million.
  • Biggest five-year swings in Assets Average: decreased 16.4% in 2022 and later soared 56.69% in 2024.
  • Acadia Pharmaceuticals' Assets Average stood at $708.9 million in 2021, then decreased by 16.05% to $595.2 million in 2022, then increased by 16.06% to $690.7 million in 2023, then soared by 56.69% to $1.1 billion in 2024, then soared by 33.74% to $1.4 billion in 2025.
  • The last three reported values for Assets Average were $1.4 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.